Literature DB >> 1373919

Models of neuronal injury in AIDS: another role for the NMDA receptor?

S A Lipton1.   

Abstract

As many as two-thirds of patients with acquired immunodeficiency syndrome (AIDS) eventually suffer from neurological manifestations, including dysfunction of cognition, movement and sensation. How can human immunodeficiency virus type 1 (HIV-1) result in neuronal damage if neurons themselves are not infected by the virus? In this article Stuart Lipton reviews a series of experiments from several different laboratories that offer related hypotheses accounting for neurotoxicity in the brains of AIDS patients. There is growing support for the existence of HIV- or immune-related toxins that directly or indirectly lead to the injury or demise of neurons via a potentially complex web of interactions between macrophages (or microglia), astrocytes and neurons. However, a final common pathway for neuronal susceptibility appears to be operative, similar to that observed after stroke, trauma and epilepsy. This mechanism involves voltage-dependent Ca2+ channels and NMDA receptor-operated channels, and therefore offers hope for future pharmacological intervention.

Entities:  

Mesh:

Substances:

Year:  1992        PMID: 1373919     DOI: 10.1016/0166-2236(92)90013-x

Source DB:  PubMed          Journal:  Trends Neurosci        ISSN: 0166-2236            Impact factor:   13.837


  37 in total

1.  Neuroprotective potential of ionotropic glutamate receptor antagonists.

Authors:  Wojciech Danysz; Chris G Parsons
Journal:  Neurotox Res       Date:  2002-03       Impact factor: 3.911

2.  HIV-1 gp120 induces antioxidant response element-mediated expression in primary astrocytes: role in HIV associated neurocognitive disorder.

Authors:  Pichili Vijaya Bhaskar Reddy; Nimisha Gandhi; Thangavel Samikkannu; Zainulabedin Saiyed; Marisela Agudelo; Adriana Yndart; Pradnya Khatavkar; Madhavan P N Nair
Journal:  Neurochem Int       Date:  2011-07-03       Impact factor: 3.921

3.  Sindbis virus-induced neuronal death is both necrotic and apoptotic and is ameliorated by N-methyl-D-aspartate receptor antagonists.

Authors:  J L Nargi-Aizenman; D E Griffin
Journal:  J Virol       Date:  2001-08       Impact factor: 5.103

4.  Behavioral characterization of GLT1 (+/-) mice as a model of mild glutamatergic hyperfunction.

Authors:  Anna Kiryk; Tomomi Aida; Kohichi Tanaka; Pradeep Banerjee; Grzegorz M Wilczynski; Ksenia Meyza; Ewelina Knapska; Robert K Filipkowski; Leszek Kaczmarek; Wojciech Danysz
Journal:  Neurotox Res       Date:  2008-01       Impact factor: 3.911

Review 5.  14-3-3s are potential biomarkers for HIV-related neurodegeneration.

Authors:  Diana Morales; Efthimios C M Skoulakis; Summer F Acevedo
Journal:  J Neurovirol       Date:  2012-07-19       Impact factor: 2.643

6.  Effects of feline immunodeficiency virus on astrocyte glutamate uptake: implications for lentivirus-induced central nervous system diseases.

Authors:  N Yu; J N Billaud; T R Phillips
Journal:  Proc Natl Acad Sci U S A       Date:  1998-03-03       Impact factor: 11.205

7.  Sleep patterns are disturbed in cats infected with feline immunodeficiency virus.

Authors:  O Prospéro-García; N Herold; T R Phillips; J H Elder; F E Bloom; S J Henriksen
Journal:  Proc Natl Acad Sci U S A       Date:  1994-12-20       Impact factor: 11.205

8.  Rapid appearance of beta-amyloid precursor protein immunoreactivity in glial cells following excitotoxic brain injury.

Authors:  R Töpper; J Gehrmann; R Banati; M Schwarz; F Block; J Noth; G W Kreutzberg
Journal:  Acta Neuropathol       Date:  1995       Impact factor: 17.088

9.  Neurovirulent simian immunodeficiency virus infection induces neuronal, endothelial, and glial apoptosis.

Authors:  D C Adamson; T M Dawson; M C Zink; J E Clements; V L Dawson
Journal:  Mol Med       Date:  1996-07       Impact factor: 6.354

10.  Human immunodeficiency virus type 1 coat protein neurotoxicity mediated by nitric oxide in primary cortical cultures.

Authors:  V L Dawson; T M Dawson; G R Uhl; S H Snyder
Journal:  Proc Natl Acad Sci U S A       Date:  1993-04-15       Impact factor: 11.205

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.